Is Regulus Therapeutics Inc. (RGLS)’s Fuel Running Low? The Stock Reaches 1 Year Low Today

April 17, 2018 - By Henry Gaston

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

Investors sentiment decreased to 1.16 in Q4 2017. Its down 0.19, from 1.35 in 2017Q3. It turned negative, as 7 investors sold Regulus Therapeutics Inc. shares while 12 reduced holdings. 10 funds opened positions while 12 raised stakes. 53.17 million shares or 9.64% less from 58.85 million shares in 2017Q3 were reported.
Deutsche Bancorp Ag holds 0% or 98 shares in its portfolio. Renaissance Technologies accumulated 137,589 shares. Moreover, Ascend Capital Ltd Limited Liability Company has 0.04% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 1.01 million shares. Laurion Capital Mngmt Limited Partnership holds 0% or 392,310 shares. 9 were accumulated by Financial Bank Of Montreal Can. Quantitative Mngmt Ltd Co holds 45,800 shares or 0% of its portfolio. Guggenheim Cap Lc owns 25,867 shares for 0% of their portfolio. Nea Mgmt Limited Liability Corp invested 0.47% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Bvf Inc Il holds 13.97M shares. Washington Trust National Bank & Trust invested in 0% or 155 shares. Royal Bankshares Of Canada reported 109,607 shares. Point72 Asset Management Lp invested in 0.01% or 1.14 million shares. Dowling & Yahnke Llc holds 11,500 shares or 0% of its portfolio. Macquarie Gru holds 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 20,000 shares. Brookstone Cap Mngmt holds 0% or 13,200 shares.

The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) hit a new 52-week low and has $0.59 target or 9.00 % below today’s $0.65 share price. The 5 months bearish chart indicates high risk for the $67.11M company. The 1-year low was reported on Apr, 17 by Barchart.com. If the $0.59 price target is reached, the company will be worth $6.04M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock increased 0.99% or $0.0063 during the last trading session, reaching $0.6455. About 460,225 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 52.76% since April 17, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Analysts await Regulus Therapeutics Inc. (NASDAQ:RGLS) to report earnings on May, 3. They expect $-0.15 earnings per share, up 60.53 % or $0.23 from last year’s $-0.38 per share. After $-0.14 actual earnings per share reported by Regulus Therapeutics Inc. for the previous quarter, Wall Street now forecasts 7.14 % negative EPS growth.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Among 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Regulus Therapeutics had 9 analyst reports since November 8, 2017 according to SRatingsIntel. BMO Capital Markets maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) on Thursday, March 8 with “Market Perform” rating. The rating was maintained by Wedbush on Wednesday, December 20 with “Buy”. The firm earned “Buy” rating on Monday, March 12 by Wedbush. As per Thursday, February 8, the company rating was maintained by Wedbush. As per Wednesday, November 8, the company rating was maintained by BMO Capital Markets. The firm has “Buy” rating by Wedbush given on Monday, December 11. As per Tuesday, March 27, the company rating was initiated by FBR Capital.

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. The company has market cap of $67.11 million. The Company’s two lead product candidates, RG-012 and RGLS4326, are in clinical development. It currently has negative earnings. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: